Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.
- A Quality-Led Approach To Drug Production Facility Design
- Reducing The Number Of Clinical Holds On Cell And Gene Therapies: Approaches For Sponsors And The FDA
- Quick Takes From Takeda Austria’s Annex 1 Rollout
- Navigating Grades And Sources Of Materials In Drug Manufacturing
- A Guide To Proactive Supplier Management In The Pharma/Biotech Industry
- Process Development With “The End In Mind” For Startups
- 2024 LIMS Trends
- Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Expansion Of MRC-5 Cells On Microcarriers Via Serial Passage In Stirred Vessels
In this application note we characterize MRC-5 cell growth on multiple microcarriers in stirred vessels and present data demonstrating feasibility of serial passage and scale-up into bioreactor expansion of MRC-5 cells.
-
Key Factors For Successful Plasmid Production
Review the distinct steps in the plasmid production workflow, along with tips for optimization from vector and strain selection to cultivation and beyond.
-
Gene Therapy Applied To Mitochondrial Disease: A Guide To Emerging Regulatory Pathways - Part 1
Learn how the FDA's expedited programs, along with the efforts of innovative companies, are paving the way for the development of effective gene therapies to address primary mitochondrial diseases.
-
Save Time And Costs With Efficient CE-SDS Analysis
Avoid relying on multiple instruments for the same type of analysis which demands a larger investment of time and money for learning, training, method development and transfer.
-
Implementing High Cell Density Cryopreservation In Your Seed Train
Simplify seed train intensification with high cell density cryopreservation. Eliminate the need for manual scale-up steps and enable risk reduction through closed banking and inoculation processes.
-
Improving Workflow Automation And Process Control
Learn about optimizing your T cell manufacturing process and reducing operating costs with rocking bioreactors using CTS OpTmizer T Cell Expansion SFM.
-
Efficient Long-Term Time-Lapse Microscopy
Read through the findings of this long-term time-lapse study investigating the formation of spheroids from U343 and MDCK cells with the help of an imaging Microhub.
-
Characterize Your Viral Vectors From Discovery To GMP Release
Simplify your workflow and achieve successful protein analysis with a faster, more robust and highly reproducible alternative method to SDS-PAGE.
-
Development And Optimization Of Suspension-Adapted 293T Cell Line
Learn how an adapted cell line can reduce costs and improve scalability in the production of lentiviral vectors for CGTs and examine its potential to produce GMP-grade lentiviral vectors.
-
Systems Employ New Single-Pass TFF Technology To Simplify Processes And Lower Costs
Single-pass TFF technology brings practical and economic advances to TFF by simplifying the process and creating new capabilities.
NEWSLETTER ARCHIVE
- 03.28.24 -- Developing Cell & Gene Therapies: Optimization-By-Design, Analytical Ultracentrifugation, Candidate Screening, And Feasibility Studies
- 03.28.24 -- What Does It Take To Make Higher Quality AAV?
- 03.27.24 -- Global Observations In The Clinical Trial Landscape
- 03.27.24 -- Inside Cellular Rejuvenation Therapies For Age-Related Diseases
- 03.26.24 -- FDA's 2024 Regulatory Outlook Recap
- Nanoscope Therapeutics Tackling Vision Loss With Ocular Gene Therapy
- ICYMI: Q1 2024’s Cell & Gene Live And Cell & Gene: The Podcast
- Inside Tenaya Therapeutics’ AAV9-Based Gene Therapy
- Rare Disease Day 2024
- Video Clips From Cell & Gene Live: 2024 Regulatory Outlook With FDA's Dr. Peter Marks And Dr. Nicole Verdun
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections